Ultragenyx Pharmaceutical Inc. (RARE)
| Market Cap | 3.28B -11.7% |
| Revenue (ttm) | 670.00M +13.5% |
| Net Income | -609.00M |
| EPS | -6.11 |
| Shares Out | 98.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,939,332 |
| Open | 31.01 |
| Previous Close | 30.68 |
| Day's Range | 30.48 - 35.00 |
| 52-Week Range | 18.29 - 42.37 |
| Beta | 0.38 |
| Analysts | Strong Buy |
| Price Target | 52.05 (+55.89%) |
| Earnings Date | Aug 4, 2026 |
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment... [Read more]
Financial Performance
In 2025, Ultragenyx Pharmaceutical's revenue was $673.00 million, an increase of 20.18% compared to the previous year's $560.00 million. Losses were -$575.00 million, 1.05% more than in 2024.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price target is $52.05, which is an increase of 55.89% from the latest price.
News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...
Ultragenyx Pharmaceutical Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Key phase III Angelman data and two gene therapy launches are expected to drive a transformative year, with profitability targeted for 2027. Strong clinical results, robust manufacturing, and strategic PRV monetization support a solid financial outlook and pipeline expansion.
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...
Ultragenyx Pharmaceutical Transcript: AGM 2026
The meeting established a quorum, presented four key proposals, and saw all measures—including director elections, incentive plan approval, auditor ratification, and executive compensation—approved by shareholders. No questions were raised during the Q&A.
Ultragenyx Pharmaceutical Transcript: Bank of America Global Healthcare Conference 2026
Revenue guidance is reaffirmed for the year, with profitability targeted for 2027 through growth in current and new products. Key catalysts include upcoming phase III Angelman data and two gene therapy launches, both supported by strong clinical and commercial preparation.
Rare disease families find roadmap to drug development at bootcamps.
Ultragenyx's Rare Bootcamp is a multi-day forum that helps families learn about conducting rare disease research and the steps that go into developing a new drug.
Rare disease families find roadmap to drug development at bootcamps
Rare disease families are increasingly driving research efforts to find treatments for their children. Ultragenyx's Rare Bootcamp gives advocates a roadmap for navigating drug development.
Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference
NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri...
Ultragenyx Pharmaceutical Earnings Call Transcript: Q1 2026
Q1 2026 revenue reached $136M, with strong growth in EVKEEZA and steady performance in CRYSVITA and DOJOLVI. 2026 revenue guidance is $730–$760M, with profitability targeted for 2027 and multiple new gene therapy launches anticipated.
Ultragenyx Pharmaceutical Earnings release: Q1 2026
Ultragenyx Pharmaceutical released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Ultragenyx Pharmaceutical Quarterly report: Q1 2026
Ultragenyx Pharmaceutical has published its Q1 2026 quarterly earnings report on May 5, 2026.
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million
Ultragenyx Pharmaceutical Slides: Corporate presentation
Ultragenyx Pharmaceutical has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Ultragenyx Pharmaceutical Proxy statement: Proxy filing
Ultragenyx Pharmaceutical filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
NOVATO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for ser...
DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026
PHILADELPHIA, April 3, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ...
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
Program to be externally funded by a venture philanthropy agreement through clinical proof-of-concept, including the Phase 1/2 study planned to begin in the second half of 2026 Program to be externall...
Ultragenyx Pharmaceutical Proxy statement: Proxy filing
Ultragenyx Pharmaceutical filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Ultragenyx Pharmaceutical Proxy statement: Proxy filing
Ultragenyx Pharmaceutical filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
Ultragenyx's gene therapy helps control ammonia levels in late-stage study
Ultragenyx Pharmaceutical said on Thursday its experimental gene therapy helped patients in a late-stage trial to better control ammonia levels linked to a rare inherited disorder.
Ultragenyx Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026
Strong commercial growth supports a robust pipeline, with pivotal Angelman and gene therapy programs advancing toward key regulatory milestones. Angelman Phase 3 design addresses placebo effect, and gene therapy durability is supported by long-term data. GSDIa and Sanfilippo approvals are expected in the second half of the year.
Ultragenyx Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference
The company is advancing a diverse rare disease pipeline, with near-term regulatory decisions expected for GSD1A and Sanfilippo, and a pivotal Angelman phase III data readout anticipated in the second half of the year. Profitability is targeted for 2027, supported by a broad commercial footprint and robust late-stage programs.
Ultragenyx Pharmaceutical Transcript: TD Cowen 46th Annual Health Care Conference
Key updates include strong progress in Angelman syndrome trials, with Aspire phase III powered for cognition and MDRI endpoints, and Aurora supporting broader labeling. Setrusumab shows promise for bone disease with accelerated approval in view. Gene therapy programs advance despite regulatory delays, with launches for Sanfilippo and GSDIa prioritized.
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - February 24, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutic...
Ultragenyx to Participate at Investor Conferences in March
NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...